Thursday, August 20, 2015

RestorGenex Corp. (RESX) Looks to Address Underserved Oncology Indications with Innovative Product Candidate

RestorGenex Corp. (OTCQX: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product candidate, RES-529, is a novel PI3K/Akt/mTOR pathway inhibitor that has completed two phase I clinical trials for the treatment of age-related macular degeneration (AMD) and is in preclinical oncology development for the treatment of glioblastoma multiforme (GBM). RestorGenex has announced plans to initiate human clinical trials in GBM in 2016. Additionally, the company’s pipeline includes RES-440, a ‘soft’ anti-androgen compound for the treatment of acne vulgaris.

Through its ongoing development programs, RestorGenex is addressing a collection of underserved markets in the biopharmaceutical industry. According to industry data, the worldwide market for the treatment of GBM in 2013 was estimated at $1 billion, and that figure is expected to climb to $4.5 billion by 2020. Due to the modest effectiveness of currently available treatment options, this market performance could provide an opportunity for RestorGenex to achieve considerable financial growth upon commercialization of RES-529. The company’s innovative PI3K pathway inhibitor has also shown promise in a number of additional indications, which RestorGenex is currently evaluating for the purpose of creating safe and effective treatments.

“The scientific research and knowledge of RES-529 continues to expand, in particular for clinical oncology applications,” Stephen M. Simes, chief executive officer of RestorGenex, stated in a news release. “These new data help to validate our plans for future studies with RES-529, as well as suggest that its analogs could also be developed for oncology indications.”

Moving forward, RestorGenex will lean on the strength of its balance sheet as it progresses toward the commercialization of its promising development pipeline. As of June 30, 2015, the company reported cash and cash equivalents of approximately $16.5 million, which it expects to sufficiently fund its operations well into the second half of 2016. RestorGenex had no outstanding debt as of its latest financial filings.

For prospective shareholders, the potential marketability of RestorGenex’s development pipeline, particularly in oncology indications, could foreshadow an opportunity for the company to achieve considerable market growth in the future. Look for the company to continue benefitting from its favorable financial position as it advances its product candidates in the months to come.

For more information, visit www.restorgenex.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html